Charles Schwab Investment Management Inc. Buys 45,936 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Charles Schwab Investment Management Inc. increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,341,773 shares of the company's stock after purchasing an additional 45,936 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.08% of Vaxcyte worth $109,838,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the period. Proficio Capital Partners LLC acquired a new stake in Vaxcyte in the fourth quarter worth $2,915,000. New York Life Investment Management LLC increased its stake in Vaxcyte by 4.1% in the fourth quarter. New York Life Investment Management LLC now owns 12,469 shares of the company's stock valued at $1,021,000 after purchasing an additional 494 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in shares of Vaxcyte during the fourth quarter valued at about $28,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Vaxcyte by 2.4% during the fourth quarter. Bank of New York Mellon Corp now owns 421,938 shares of the company's stock valued at $34,540,000 after purchasing an additional 9,888 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Up 5.2 %

Shares of NASDAQ:PCVX traded up $3.62 during mid-day trading on Wednesday, hitting $73.47. 936,587 shares of the company traded hands, compared to its average volume of 1,184,075. The stock has a 50-day moving average price of $82.82 and a two-hundred day moving average price of $94.59. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The stock has a market cap of $9.46 billion, a P/E ratio of -16.02 and a beta of 1.02.

Remove Ads

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PCVX shares. Needham & Company LLC restated a "buy" rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Guggenheim reissued a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday. Finally, The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They set a "buy" rating and a $135.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $147.50.

Insider Buying and Selling

In other news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now directly owns 7,175 shares of the company's stock, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,250 shares of company stock worth $4,550,258. 3.10% of the stock is owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.